Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously announced registered direct offering of 14,700,000 shares of common stock at a purchase price of $2.05 per share. Gross proceeds from the offering were approximately $30 million, before deducting placement agent fees and other offering expenses.
Titan Partners Group, a division of American Capital Partners, acted as the sole placement agent for the offering.
"We believe that this level of support from leading institutional investors validates our efforts and the positive data we have generated to date in three major age-related degenerative disorders," stated Lisa Ricciardi, president and CEO of Cognition. "With this additional capital, we look forward to advancing zervimesine for the treatment of serious neurodegenerative disorders."
The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-268992) previously filed with the U.S. Securities and Exchange Commission (the "SEC") and declared effective on January 3, 2023. The offering of the shares of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement, which was filed with the SEC and is available on the SEC's website located at www.sec.gov. Electronic copies of the final prospectus supplement may also be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Zervimesine (CT1812)Zervimesine (CT1812) is an investigational, oral, once-daily pill in development for the treatment of CNS diseases such as Alzheimer's disease and dementia with Lewy bodies (DLB). While these diseases have different symptoms, both are associated with the buildup of certain proteins in the brain, Aβ and ɑ-synuclein. As these proteins bind to ...
